Ironwood Pharmaceuticals Inc (IRWD) Stock Analysis

Ironwood Pharmaceuticals Inc (IRWD) is a publicly traded company in the HEALTHCARE sector. It trades at $3.28, carries a market capitalization of $569.56M, a price-to-earnings ratio of 5.58. This page summarizes the public market data, fundamentals, and frequently asked questions for IRWD, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - DRUG MANUFACTURERS - SPECIALTY & GENERIC

Exchange: NASDAQ

Key Metrics

Market Sentiment

Ironwood Pharmaceuticals Inc currently has a Neutral sentiment score of 0.03.

About Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals, Inc. is a leading biotechnology company based in Boston, Massachusetts, focused on developing and commercializing innovative gastrointestinal therapies. With a robust pipeline and a strong commitment to addressing unmet medical needs in the GI sector, the company has established a significant market presence, particularly with its flagship product, Linzess (linaclotide). Ironwood's strategic focus on research and collaboration not only enhances its therapeutic portfo...

GNG Research Analysis

GNG Research scores Ironwood Pharmaceuticals Inc (IRWD) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for IRWD.

Frequently Asked Questions

Does IRWD pay dividends?

Ironwood Pharmaceuticals Inc (IRWD) does not currently pay a regular dividend.

What is IRWD's P/E ratio?

Ironwood Pharmaceuticals Inc has a price-to-earnings (P/E) ratio of 5.58.

What is IRWD's market cap?

Ironwood Pharmaceuticals Inc (IRWD) has a market capitalization of $569.56M with a current stock price of $3.28.